This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 3 of 4 for:    newton-cheh

Genetics of QT Response to Moxifloxacin (MOXIGEN)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Christopher Newton-Cheh, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01936480
First received: August 30, 2013
Last updated: June 15, 2017
Last verified: June 2017
  Purpose
The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in healthy subjects using moxifloxacin.

Condition Intervention Phase
Cardiac Arrhythmias Drug: Moxifloxacin 400mg once time Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Investigator, Outcomes Assessor
Primary Purpose: Prevention
Official Title: Genetics of QT Response to Moxifloxacin

Resource links provided by NLM:


Further study details as provided by Christopher Newton-Cheh, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • QT interval duration [ Time Frame: 6 Hours ]
    We will measure the QT interval on ECG up to 6 hours after administration of moxifloxacin or placebo


Estimated Enrollment: 160
Study Start Date: October 2013
Estimated Study Completion Date: October 2019
Estimated Primary Completion Date: September 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Moxifloxacin group
Healthy volunteers with QT genotype score in the highest or lowest quintile
Drug: Moxifloxacin 400mg once time
Other Name: Avelox
Placebo Comparator: Placebo Group
Healthy volunteers with QT genotype score in the highest or lowest quintile
Drug: Placebo

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers
  • Genotype in the highest and lowest quintiles of genetic predictors of QT interval duration
  • Able to swallow pills

Exclusion Criteria:

  • Inability to provide informed consent
  • Prior known cardiovascular, renal, hepatic disease
  • Personal or family history of sudden cardiac death
  • Current use of prescribed or over-the-counter medications as well as recreational drugs
  • Resting bradycardia (defined as resting heart rate < 50 bpm)
  • Conduction disease (QRS > 100ms)
  • QTc prolongation on electrocardiography (QTc > 500msec)
  • Abnormal potassium or magnesium serum level
  • Abnormal renal or liver function tests
  • Women who are nursing, pregnant or planning to become pregnant during the study period
  • Tendon disorder or rupture
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01936480

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Christopher Newton-Cheh, MD, MPH Massachusetts General Hospital
  More Information

Responsible Party: Christopher Newton-Cheh, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01936480     History of Changes
Other Study ID Numbers: 2009A059013
Study First Received: August 30, 2013
Last Updated: June 15, 2017

Additional relevant MeSH terms:
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Moxifloxacin
Fluoroquinolones
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on June 27, 2017